Key Takeaways COR will acquire EyeSouth's retina business for $1.1B to expand its RCA platform.The deal adds retina physicians, boosting RCA's network, clinical trials access and care capabilities.The acquisition is expected to be slightly accretive to adjusted EPS within 12 months of closing.Cencora, Inc. (COR) recently announced a definitive agreement to acquire EyeSouth Partners’ retina business for $1.1 billion, marking a strategic step to expand its Retina Consultants of America (“RCA”) platform. The d ...

Drug distributor Cencora said on Monday it would buy the retina business of eye care network EyeSouth Partners for $1.1 billion, expanding its eye care unit. ...

TimesSquare Capital Management, an equity investment management company, released its “U.S. Focus Growth Strategy” fourth-quarter 2025 investor letter. A copy of the letter can be downloaded here. The strategy returned -3.55% (gross) and -3.76% (net) in the fourth quarter compared to a -3.70% return for the Russell Midcap Growth Index. In 2025, the strategy returned 14.84% (gross) and 13.88% (net) compared to 8.66% for the index. Global equity markets ended the quarter on a positive note, with Europe leadin ...

Core Viewpoint - Cencora, Inc. announces the retirement of James F. Cleary as Executive Vice President and Chief Financial Officer effective June 30, 2026, while reaffirming its fiscal 2026 financial guidance for adjusted diluted EPS in the range of $17.45 to $17.75 [1][3]. Leadership Transition - James F. Cleary has served as CFO since November 2018 and joined Cencora in February 2015 after the acquisition of MWI Veterinary Supply, where he was CEO for over a decade [2]. - The company has engaged an executive search firm to identify potential successors, and Cleary will assist in the transition process until the end of 2026 [1][3]. Financial Guidance - Cencora reaffirms its adjusted diluted EPS guidance for fiscal year 2026, maintaining a range of $17.45 to $17.75 [3]. Company Overview - Cencora is a leading global pharmaceutical solutions organization with over 51,000 employees and annual revenue exceeding $300 billion, ranked 10 on the Fortune 500 and 18 on the Global Fortune 500 [4].

Group 1 - The company reported a 21% growth in its U.S. segment for the most recent quarter, indicating strong performance [1] - The company announced the acquisition of the remaining portion of OneOncology, which it did not previously own, enhancing its market position [1] - The acquisition of both Retina Consultants of America and OneOncology is expected to strengthen the company's MSO strategy [2]

Summary of Cencora Conference Call Company Overview - **Company**: Cencora - **Industry**: Healthcare Technology and Distribution Key Points Financial Performance - Cencora reported a **21% growth** in its U.S. segment for the most recent quarter, indicating strong underlying business trends [2][3] - The company announced the acquisition of the remaining portion of **OneOncology**, enhancing its position in the specialty market [2][3] - Following the OneOncology acquisition, Cencora increased its consolidated guidance for the year by **3.5%**, with operating income growth guidance raised to **14%-16%** [3][4] Strategic Initiatives - The acquisition of OneOncology and **Retina Consultants of America (RCA)** is seen as a natural evolution of Cencora's specialty business, transitioning from distribution to Group Purchasing Organization (GPO) and now to Managed Service Organization (MSO) [3][6] - Cencora is focused on **growth-oriented investments** in specialty services, which are driving the company's growth [6][8] Market Trends - The oncology market is experiencing strong organic growth driven by factors such as an **aging population**, multi-therapy treatments, and new innovations including biosimilars [8][10] - Cencora's MSO strategy positions it well to capitalize on these trends, particularly in the physician-administered oncology market [8][10] Synergies and Operational Efficiency - With full ownership of RCA and OneOncology, Cencora aims to drive synergies between the two businesses, particularly in clinical trial capabilities and back-office operations [10][11] - The company emphasizes a long-term investment perspective, focusing on enhancing operational efficiencies and data analytics capabilities [12][16] Contracting and Pricing Strategy - Cencora's strategic global sourcing team successfully maintained gross profit dollars through effective contracting, despite challenges posed by the first round of IRA negotiated drugs [21][25] - The company has established terms in contracts to renegotiate in case of significant price changes, ensuring a defendable value proposition [27][28] Generics and Biosimilars Market - The generics market has shown **moderation in deflation**, with manufacturers prioritizing their portfolios, leading to a stable environment [36][38] - Cencora anticipates growth opportunities in both generics and biosimilars, which will complement branded innovation [38][39] Independent Pharmacies - Cencora has contributed to the sustainability of independent pharmacies by providing services and purchasing scale, allowing them to remain profitable [66][69] - The dynamics of independent pharmacy ownership have evolved, with multiple pharmacies often owned by a single entity leveraging distributor services [69] GLP-1 Market - The GLP-1 market is a significant growth area for Cencora, but it remains a minimally profitable segment, with no expected changes in profitability for fiscal year 2026 [70][71] Additional Insights - Cencora's focus on long-term investments and strategic acquisitions positions it well for future growth in the healthcare distribution sector [12][16] - The company is actively exploring bolt-on acquisitions to strengthen its specialty and pharmaceutical-centric strategies [19][20]

Core Insights - Cencora is being presented at a Barclays event, indicating the company's engagement with investors and analysts [1] - Glen Santangelo, an analyst with over two decades of experience covering Cencora, has recently resumed coverage of the stock after a hiatus of nearly three months [1] Company Overview - The presentation features key executives from Cencora, including CFO Jim Cleary and Senior Vice President Bennett Murphy, highlighting the leadership team's involvement in investor relations [2] - The company is positioned to discuss its strategies and performance, suggesting a proactive approach to investor communication [2]

Core Insights - Cencora's recent earnings report showed an adjusted earnings per share of $4.08, slightly beating the Zacks Consensus Estimate of $4.07, and reflecting a year-over-year increase of 9.4% [3] - The company's total revenues reached $85.93 billion, marking a 5.5% increase year over year, which was nearly in line with expectations [4] Revenue and Segment Analysis - U.S. Healthcare Solutions segment revenues were $76.2 billion, up 5% year over year, driven by market growth and increased sales of GLP-1 drugs and specialty products [5] - International Healthcare Solutions segment revenues amounted to $7.6 billion, reflecting a 7.6% year-over-year increase, with a reported basis increase of 9.6% and a constant currency increase of 6.2% [7] Margin and Income Analysis - Cencora reported an adjusted gross profit of $3 billion, an 18.1% increase year over year, with an adjusted gross margin of 3.48%, up 37 basis points [8] - Adjusted operating income was $1.1 billion, up 11.9% year over year, with an adjusted operating margin of 1.24%, expanding 8 basis points from the previous year [8] Financial Position - The company ended the fiscal first quarter with cash and cash equivalents of $1.75 billion, down from $4.36 billion in the previous quarter [9] - Net cash used in operating activities was $2.31 billion, compared to $2.72 billion a year ago [9] Dividend Declaration - Cencora's board declared a quarterly dividend of 60 cents per share, payable on March 2, 2026, to shareholders of record by February 13, 2026 [11] Fiscal Year 2026 Guidance - The company updated its fiscal 2026 guidance, projecting adjusted earnings per share in the range of $17.45-$17.75 and total revenues to rise by 7%-9%, an increase from the previous guidance of 5%-7% [12] - Adjusted operating income is now expected to improve by 11.5%-13.5%, up from the previous guidance of 8%-10% [13] Market Performance and Estimates - Recent estimates for Cencora have shown a downward trend, indicating a potential shift in market sentiment [14][16] - Cencora holds a Zacks Rank 3 (Hold), suggesting an expectation of an in-line return in the coming months [16] Industry Comparison - Cencora is part of the Zacks Medical Services industry, where HCA Healthcare reported revenues of $19.51 billion, a year-over-year increase of 6.7% [17] - HCA's expected earnings for the current quarter are $7.18 per share, reflecting an 11.3% year-over-year change [18]

Investment Rating - The report indicates a positive investment outlook for the healthcare services industry, with a projected 9.6% year-over-year growth in transaction activity for 2025, totaling approximately 747 transactions [7]. Core Insights - The healthcare services sector is experiencing a shift, with private equity (PE) exits increasing by 17.1% in number and 14.1% in value year-over-year, despite a slight decline in overall transaction value by 1.6% [7]. - Significant transactions in 2025 include Cencora's acquisition of OneOncology for $7.4 billion, with an EV/EBITDA multiple of 19x, and Ascension's acquisition of AMSURG for $3.9 billion at a 15.8x multiple [8]. - The report highlights a notable increase in transaction volume in specialized care and pharmacy sectors, with advanced care leading the growth at 142.9% year-over-year [13]. Summary by Sections PE Activity - The report outlines that the healthcare services transaction volume is expected to grow, with advanced care and specialty pharmacies showing significant increases [13]. - However, the report notes a decline in transaction volume for physician practice management (PPM) by 18%, driven by weaknesses in specific specialties such as gastroenterology and dentistry [14]. Market Trends - The report emphasizes that the valuation multiples for public hospitals and payers are near long-term averages, with expectations of a decline in 2026 due to reimbursement challenges [25]. - The adoption of AI is anticipated to reduce administrative costs, benefiting both payers and providers, although providers are currently leading in AI adoption rates [25]. Strategic Focus - There is a growing interest in outpatient surgery centers (ASCs) and PPM acquisitions, with expectations that implementing AI capabilities will enhance operational efficiency and long-term valuation prospects [26]. - The report suggests that the regulatory environment, particularly in states like California, is impacting transaction timelines and investor sentiment [15][18].

Core Insights - Cencora, Inc. (COR) has agreed to merge its subsidiary MWI Animal Health with Covetrus, valuing MWI at an enterprise value of $3.5 billion [1][9][10] - The merger aims to enhance operational efficiency and growth in the animal health ecosystem by combining MWI's distribution capabilities with Covetrus' technology [2][12] Company Summary - The transaction allows Cencora to unlock capital from MWI while retaining a 34.3% equity stake in the combined entity, which strengthens its balance sheet with $1.25 billion in cash, $800 million in preferred equity, and $1.45 billion in common equity [4][11] - Cencora's market capitalization stands at $70 billion, reflecting its significant position in the market [7] - The merger is expected to create a more integrated platform that improves access and innovation in the animal health market [12][13] Industry Summary - The global animal health market is projected to grow from $62.89 billion in 2024 to $112.33 billion by 2030, with a compound annual growth rate (CAGR) of 10.46% [15] - Key drivers of market growth include increased spending on animal healthcare, the integration of artificial intelligence, and rising concerns about animal diseases and zoonotic infections [16] - Cencora's recent fiscal first-quarter results showed mixed performance, with earnings exceeding estimates and revenues meeting expectations, supported by growth in healthcare solutions and specialty products [17]